Objective:

To explore the persistence and complications of juvenile idiopathic arthritis-associated uveitis (JIAU) in adults.

Approach:

• Overview of JIAU: JIAU is the most common systemic disease-associated uveitis in childhood, often persisting into adulthood with significant ocular morbidity.
• Adult Phenotype: Many adults with JIAU experience ongoing inflammation, treatment dependence, and complications from childhood disease.
• Complications and Visual Impairment: Common complications include cataract, glaucoma, and macular edema, with a significant incidence of visual impairment reported.
• Treatment Considerations: Topical corticosteroids are first-line treatment, but systemic immunomodulatory therapy is recommended for uncontrolled inflammation.
• Transition to Adult Care: Transitioning patients may have discordant ocular and articular disease activity, necessitating careful management of immunosuppression.

Key Findings:

• 52% of adults with JIAU had ongoing inflammation at their final visit, according to the Oray et al. study.
• Complications such as cataract and glaucoma were prevalent, with 72% of eyes having at least one ocular complication, as reported in the same study.
• The pooled incidence of severe visual impairment was 16.6% after approximately 18 years of follow-up, based on a systematic review and meta-analysis.
• Discontinuation of biologic therapy poses a risk of treatment failure, with 68% of patients experiencing failure after withdrawal, as noted in the literature.

Interpretation:

The findings indicate that JIAU can persist into adulthood with significant complications, and management strategies must consider the long-term effects of childhood disease.

Limitations:

• The study relies on retrospective evaluations, which may introduce bias, as stated in the source.
• Long-term prospective data are still needed to fully understand the natural history of JIAU, according to the findings.

Conclusion:

JIAU in adults requires ongoing management and monitoring due to the potential for persistent inflammation and complications.

Sources:

• Oray et al. Study
• Raymond et al. Report
• ADJUST Trial